The correlation between metabolic syndrome quantification scores and numerous laboratory parameters related to this syndrome

Branko  Srećković; Igor  Mrdović; Ivan  Soldatović; Mirko  Resan; Nenad  Janeski; Emina  Čolak; Hristina  Janeski; Mirjana  Šumarac-Dumanović; Miloš  Joković; Nebojša  Ivanović; Jasna  Gačić; Vesna Dimitrijević-Srećković

doi:10.2298/VSP180626132S

Branko Srećković Clinical Center “Bežanijska kosa”, Belgrade, Serbia
Igor Mrdović Clinical Centre of Serbia, Clinic for Emergency Internal Medicine, Belgrade, Serbia
Ivan Soldatović University of Belgrade, Institute for Medical Statistics and Informatics, Belgrade, Serbia
Mirko Resan Miltary Medical Academy, Clinic for Ophthalmology, Belgrade, Serbia
Nenad Janeski Clinical Centre Zemun, Belgrade, Serbia
Emina Čolak Clinical Centre of Serbia, Institute of Medical Biochemistry, Belgrade, Serbia
Hristina Janeski University Children's Hospital, Belgrade, Serbia
Mirjana Šumarac-Dumanović University of Belgrade, Faculty of Medicine, Belgrade, Serbia
Miloš Joković University of Belgrade, Faculty of Medicine, Belgrade, Serbia
Nebojša Ivanović Clinical Center “Bežanijska kosa”, Belgrade, Serbia
Jasna Gačić Clinical Center “Bežanijska kosa”, Belgrade, Serbia
Vesna Dimitrijević-Srećković University of Belgrade, Faculty of Medicine, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP180626132S

Keywords: biomarkers, homocysteine, metabolic syndrome, risk assessment, risk factors

Abstract

Background/Aim. Metabolic syndrome (MS) is characterized by basic cluster risk factors – waist circumference (WC), glucoregulation disorders, hypertension, hypertriglyceridemia, low HDL-cholesterol followed by associated factors such as insulin resistance (IR), C-reactive protein (CRP), uric acid, plasminogen activator inhibitor-1 (PAI-1), fibrinogen, hyperhomocysteinemia (HHcy), nonalcoholic fatty liver disease (NAFLD) and microalbuminuira. The aim of this study was to analyze basic and associated factors of MS in patients with and without MS as well as correlation of siMS score, siMS risk score with basic and confounding factors of MS. Methods. The study included 148 overweight [body mass index (BMI) 25–30 kg/m² and obese patients (BMI > 30 kg/m²)], age 30–75 years, classified into two groups: I – with MS (68 patients); II – without MS (80 patients). For quantification of MS, siMS score was used as a method, and siMS risk score was used as atherosclerotic complications risk indicator. Results. Patients with MS had statistically higher values of WC, hypertension, triglycerides (p < 0.001), glycemia (p = 0.006), as well as values of associated factors of MS [homeostatic model assessment (HOMA-IR)] (p = 0.002), CRP (p = 0.01), uric acid (p < 0.001), alanin transaminase (ALT) (p = 0.007) i gammaglutamyl transferase (GGT) (p = 0.001) and lower values of HDL-cholesterol (p < 0.001) compared to patients without MS. siMS score has shown correlation with associated factors of MS (log HOMA IR, logCRP, uric acid, (p < 0.001), fibrinogen (p = 0.005), liver enzymes logALT (p = 0.001) and log GGT (p < 0.001) and renal parametars (creatinine (p = 0.013) and serum protein (p = 0.006). siMS risk score correlated significantly with homocysteine, platelets, uric acid, blood urea nitrogen, albumins and proteins. Conclusion. In our study we found that patients with MS had higher values of associated factors of MS (HOMA-IR, CRP, uric acid, ALT, GGT), which was confirmed by correlation with siMS score. siMS score further indicated that IR, CRP, fibrinogen, uric acid and NAFLD are associated factors of MS. siMS risk score is another score that indicated that obesity and hyperprotein diet aggravates HHCy with age, increasing the risk for renal dysfunction and promoting atherosclerotic complications.

References

Kumar A, Palfrey HA, Pathak R, Kadowitz PJ, Gettys TW, Murthy SN. The metabolism and significance of homocysteine in nu-trition and health. Nutr Metab (Lond) 2017; 14: 78.

Catena C, Colussi G, Nait F, Capobianco F, Sechi LA. Elevated Homocysteine Levels Are Associated With the Metabolic Syndrome and Cardiovascular Events in Hypertensive Pa-tients. Am J Hypertens 2015; 28(7): 943–50.

Fonseca V, Dicker-Brown A, Ranganathan S, Sing W, Barnard RJ, Fink L, et al. Effects of high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism 2000; 49(6): 736–41.

Oron-Herman M, Rosenthal T, Sela BA. Hyperhomocysteinemia as a component of syndrome X. Metabolism 2003; 52(11): 1491–5.

Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic szndrome and risk incident cardiovascu-lar events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49(4): 403–14.

Garcin JM, Cremades S, Garcia-Hejl C, Bordier L, Dupuy O, Ma-yaudon H, et al. Is hyperhomocysteinemia an additional risk factor of the metabolic syndrome? Metab Syndr Relat Disord 2006; 4(3): 185–95.

Srećković B, Soldatovic I, Colak E, Mrdovic I, Sumarac-Dumanovic M, Janeski H, et al. Homocysteine is the confounding factor of metabolic syndrome-confirmed by siMS score. Drug Metab Pers Ther 2018; 33(2): 99–103.

Soldatovic I, Vukovic R, Culafic D, Gajic M, Dimitrijevic-Sreckovic V. siMS Score: Simple Method for Quantifying Metabolic Syndrome. PLoS One 2016; 11(1): e0146143.

de Carvalho SC, Muniz MT, Siqueira MD, Siqueira ER, Gomes AV, Silva KA, et al. Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). Nutr J 2013; 12: 37.

Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyper-homocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997, 95: 1119–21.

Papatheodorou L, Weiss N. Vascular oxidant stress and inflam-mation in hyperhomocysteinemia. Antioxid Redox Signal 2007; 9(11): 1941–58.

Sreckovic B, Sreckovic VD, Soldatovic I, Colak E, Sumarac-Dumanovic M, Janeski H, et al.. Homocysteine is a marker for metabolic syndrome and atherosclerosis. Diabetes Metab Syndr 2017; 11(3): 179–82.

Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7(6): 846–58.

McCully KS. Vascular pathology of homocysteinemia: implica-tions for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56(1): 111–28.

Faeh D, Chiolero A, Paccaud F. Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about? Swiss Med Wkly 2006; 136(47–48): 745–56.

Li Y, Jiang C, Xu G, Wang N, Zhu Y, Tang C, et al. Homocys-teine upregulates resistin production from adipocytes in vivo and in vitro. Diabetes 2008; 57(4): 817–27.

Sheu WH, Lee WJ, Chen YT. Plasma homocysteine concentra-tions and insulin sensitivity in hypertensive subjects. Am J Hypertens 2000; 13(1Pt 1): 14–20.

Srećković B. Determination of homocysteine level as an inde-pendent risk factor for coronary heart disease [subspeciality thesis]. Belgrade: Faculty of Medicine, University of Belgrade; 2010. (Serbian)

Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to defini-tion. Circulation 2004; 109(3): 433–8.

Gowdaiah PK, Mamatha TR, Nirgude D, Hosamani PB. High sen-sitivity C-reactive protein in metabolic syndrome. Int J Adv Med 2016; 3(3): 607–10.

Mauras N, Delgiorno C, Kollman C, Bird K, Morgan M, Sweeten S, et al. Obesity without established comorbidities of the meta-bolic syndrome is associated with a proinflammatory and pro-thrombotic state, even before the onset of puberty in children. J Clin Endocrinol Metab 2010; 95(3): 1060–8.

Dimitrijević Srećković V. Metabolic syndrome, prediabetes and non alcoholic fatty liver diseases- treatment by Mediterranean diet. In: Dimitrijević Srećković V, Vukašinović V, editors. FAST-ING-A WAY TO LIFE- Christian fasting as a method for preventing and treating diabetes, atherosclerosis and cancer. Vrnjci: Interklima-grafika; 2013. p. 37–49.

Čolak E, Pap D, Majkić Singh-N, Obradović I. The Association of obesity and liver enzyme activities in a student population at Increased Risk for Cardiovascular Disease. J Med Biochem 2013; 32(1): 26–31.

Ciba I, Widhalm K. The Association between the non-alcoholic fatty liver disease and insulin resistance in obese children and 20 adolescents. Acta Pediatr 2007; 96: 109–12.

Garcia-Tevijano ER, Berasain C, Rodriguez JA, Corrales FJ, Arias R, Martin-Duce A, et al. Hyperhomocysteinemia in liver cirrho-sis: mechanisms and role in vascular and hepatic fibrosis. Hy-pertension 2001; 38(5): 1217–21.

Pacana T, Cazanave S, Verdianelli A, Patel V, Min HK, Mirshahi F, et al. Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease. PLoS One 2015; 10(8): e0136822.

Dimitrijević-Srećković V. Metabolic sindrome in children and adolescents. In: Nedeljković S, editor. Yugoslav study of athero-sclerosis precursors in school children, 20 years of follow-up. Belgrade: Faculty of Medicine, University of Belgrade; 2011. p. 731–45. (Serbian)

Berstad P, Konstantinova SV, Refsum H, Nurk E, Vollset SE, Tell GS, et al. Dietary fat and plasma total homocysteine concen-trations in 2 adult age groups: the Hordaland Homocysteine Study. Am J Clin Nutr 2007; 85(6): 1598–605.

Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, et al. Serum homocysteine levels are associated with the development of (micro)albuminuria: the Hoorn study. Arteri-oscler Thromb Vasc Biol 2001; 21(1): 74–81.

Dimitrijević-Srećković V. Mediterranean cardioprotective nutri-tion. In: Nedeljković S, editor. Yugoslav study of atherosclerosis precursors in school children, 20 years of follow-up. Belgrade: Faculty of Medicine, University of Belgrade; 2011. p.

Han L, Liu Y, Wang C, Tang L, Feng X, Astell-Burt T, et al. Determinants of hyperhomocysteinemia in healthy and hyper-tensive subjects: A population-based study and systematic re-view. Clin Nutr 2017; 36(5): 1215–30.